Total Valuation
Nektar Therapeutics has a market cap or net worth of CHF1.88B. The enterprise value is CHF1.76K.
Market CapCHF1.88B
Enterprise ValueCHF1.76K
Share Statistics
Nektar Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders2.95%
Owned by Institutions48.30%
Financial Efficiency
Nektar Therapeutics’s return on equity (ROE) is -1.83 and return on invested capital (ROIC) is -52.82%.
Return on Equity (ROE)-1.83
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-52.82%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee876.70K
Profits Per Employee-2.60M
Employee Count63
Asset Turnover0.20
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nektar Therapeutics is ―. Nektar Therapeutics’s PEG ratio is -0.36.
PE Ratio―
PS Ratio12.91
PB Ratio7.94
Price to Fair Value7.94
Price to FCF-3.42
Price to Operating Cash Flow-9.49
PEG Ratio-0.36
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 55.23M and earned -164.08M in profits. Earnings per share was -9.73.
Revenue55.23M
Gross Profit55.23M
Operating Income-130.77M
Pretax Income-164.21M
Net Income-164.08M
EBITDA-137.00M
Earnings Per Share (EPS)-9.73
Cash Flow
In the last 12 months, operating cash flow was -233.79M and capital expenditures -262.00K, giving a free cash flow of -234.05M billion.
Operating Cash Flow-233.79M
Free Cash Flow-234.05M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Nektar Therapeutics upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Nektar Therapeutics as a current ratio of 4.97, with Debt / Equity ratio of 15.05%
Current Ratio4.97
Quick Ratio4.97
Debt to Market Cap0.12
Net Debt to EBITDA-0.98
Interest Coverage Ratio-4.99
Taxes
In the past 12 months, Nektar Therapeutics has paid -138.00K in taxes.
Income Tax-138.00K
Effective Tax Rate<0.01
Enterprise Valuation
Nektar Therapeutics EV to EBITDA ratio is -6.18, with an EV/FCF ratio of -4.06.
EV to Sales15.34
EV to EBITDA-6.18
EV to Free Cash Flow-4.06
EV to Operating Cash Flow-4.06
Balance Sheet
Nektar Therapeutics has CHF684.34M in cash and marketable securities with CHF135.93M in debt, giving a net cash position of CHF548.41M billion.
Cash & Marketable SecuritiesCHF684.34M
Total DebtCHF135.93M
Net CashCHF548.41M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF5.32
Margins
Gross margin is 99.36%, with operating margin of -236.77%, and net profit margin of -297.07%.
Gross Margin99.36%
Operating Margin-236.77%
Pretax Margin-297.32%
Net Profit Margin-297.07%
EBITDA Margin-248.05%
EBIT Margin-249.91%
Analyst Forecast
The average price target for Nektar Therapeutics is CHF118.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF118.27
Price Target Upside― Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―